A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

About this trial
This is an interventional treatment trial for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) focused on measuring Carnitine Palmitoyl Transferase (CPT) I Deficiency, Carnitine Palmitoyl Transferase (CPT) II Deficiency, Carnitine/acylcarnitine Translocase (CACT) Deficiency, Very Long Chain Acyl-coenzyme A Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxyacyl-coenzyme A Dehydrogenase (LCHAD) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency
Eligibility Criteria
Inclusion Criteria for Main Study: Males and females, from 0 (including newborns) to < 18 years of age Confirmed diagnosis of LC-FAOD Have a caregiver(s) willing and able to assist in all applicable study requirements Have a legally authorized representative willing and able to provide written informed consent after the nature of the study has been explained and prior to any research-related procedures, and the study participant to be able to provide age-appropriate written assent Have ANY ONE of the following significant clinical manifestations of LC-FAOD: At least 2 in the prior year, or 3 in the prior 2 years, of severe major episodes of metabolic decompensation (eg, hypoglycemia, rhabdomyolysis, or exacerbation of cardiomyopathy, requiring ER/urgent care unit visits or hospitalizations) Recurrent symptomatic hypoglycemia (clinical symptoms of hypoglycemia) requiring intervention Susceptibility to hypoglycemia after short periods of fasting (less than 4 to 12 hours, depending on age) Evidence of functional cardiomyopathy requiring ongoing medical management or clinical manifestation of heart failure Sibling(s) with the same pathogenic variant who presented with MCEs Participant with pathogenic variants that are known or suspected to be associated with absent or severely reduced enzyme activity or with severe disease manifestations. From the time of informed consent to 5 days after the last dose of study drug in this study, females of childbearing potential and fertile males must consent to use highly effective methods of contraception. If female, agree not to become pregnant. If male, agree not father a child or donate sperm Inclusion Criteria for Liver Substudy: Enrollment in the Main Study of Study UX007-CL302 Age > 2 years Liver fat content ≥ 2% and < 20% PDFF as assessed by 1 H-MRS Body mass index < 95th percentile Able to comply with instructions (remaining still during scan) and requirements (eg, constraints on recent meals, no metallic items or implanted devices in the body, no recent contrast agents) for liver 1 H-MRS scan Exclusion Criteria for Main Study: Enrolled in a clinical study involving concurrent use of an investigational drug product within 30 days before Screening Use of a prohibited medication (eg, valproate products or pancreatic lipase inhibitors) within 30 days before Screening, or unwilling to avoid a prohibited medication or other substance that may confound study objectives Treatment with triheptanoin within 60 days of Screening History of known hypersensitivity to triheptanoin or MCT Caregiver unwilling or unable to sign informed consent, or release of medical records, or follow study procedures Have any co-morbid conditions, including unstable major organ-system disease(s) that in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives. History of metabolic decompensation(s) with metabolic acidosis, hyperammonemia, and/or liver enzyme elevations does not constitute an exclusion criterion unless in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives Have a diagnosis of pancreatic insufficiency Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study Exclusion Criteria for Liver Substudy: Acute or chronic liver disease other than LC-FAOD that presents with increased risk of liver fat (eg, hepatic cirrhosis, viral toxic or drug hepatitis, diabetes mellitus) and/or metabolic syndrome Need for anesthesia/sedation to perform liver 1 H-MRS
Sites / Locations
- General University Hospital in Prague-GUH (Všeobecná fakultní nemocnice v Praze- VFN)Recruiting
- Universität FreiburgRecruiting
- Instytut Pomnik-Centrum Zdrowia Dziecka
- Gdańksi Uniwersytet MedycznyRecruiting
- King Faisal Specialist Hospital & Research Centre
- Sant Joan de Deu Hospital (SJD)Recruiting
- University Hospital Santiago de CompostelaRecruiting
- University Hospital 12 de OctubreRecruiting
- Gazi UniversityRecruiting
- Ege UniversityRecruiting
- Istanbul Universitesi Istanbul Tip Fakultesi HastanesiRecruiting
- Cerrahpasa Medical FacultyRecruiting
- Great Ormond Street HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Triheptanoin
MCT
Participants will be given prescriptions for Triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.